Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Whether education modifies genetic influences on cognition has not been fully explored, especially in non-European populations. Using the older adult cohort from the Taiwan Biobank of East Asian populations, this study aimed to investigate the modifying effect of education on the association of the apolipoprotein E (APOE) ε4 allele and polygenic scores (PGS) for Alzheimer's disease (PGS), cognitive performance (PGS), education attainment (PGS), and schizophrenia (PGS) with cognitive ability. Participants aged > 60 years were included in this cohort study. The Mini-Mental State Examination (MMSE) was used for cognitive assessment of 27,343 individuals at baseline (mean age: 63.57 years), and follow-up data were available for 6,273 participants. Linear regression models were employed to examine the association between genetic factors and baseline MMSE scores and MMSE decline and further stratified by education to test the modifying effect. The APOE ε4 allele, PGS, PGS, PGS, and PGS were associated with baseline MMSE but not MMSE decline. The positive effects of the PGS and PGS on baseline MMSE, and negative effect of the PGS on baseline MMSE and MMSE decline were higher for individuals with lower education. This study demonstrated the transferability of European-derived PGSs to older community samples of East Asian populations. Education mitigates specific genetic effects on cognition, which supports and extends cognitive reserve theory. Promoting cognitive health in older adults by extending education is of importance, especially for populations with higher genetic predispositions and lower education attainment.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10519-025-10229-xDOI Listing

Publication Analysis

Top Keywords

baseline mmse
16
pgs pgs
16
pgs
12
mmse decline
12
education
9
cognitive ability
8
older adults
8
east asian
8
asian populations
8
apoe ε4
8

Similar Publications

Background: Atrial fibrillation (AF) is the most common arrhythmia in adults, with incidence increasing with age. Cognitive impairment (CoI) and dementia share risk factors with AF. Meta-analyses indicate that AF increases the risk of CoI by 2.

View Article and Find Full Text PDF

BackgroundAlzheimer's disease (AD) is the most common neurodegenerative disorder. While AD diagnosis traditionally relies on clinical criteria, recent trends favor a precise biological definition. Existing biomarkers efficiently detect AD pathology but inadequately reflect the extent of cognitive impairment or disease heterogeneity.

View Article and Find Full Text PDF

BackgroundTherapeutic plasma exchange (TPE) with albumin replacement has emerged as a potential treatment for Alzheimer's disease (AD). The AMBAR trial showed that TPE could slow cognitive and functional decline, along with changes in core and inflammatory biomarkers in cerebrospinal fluid.ObjectiveTo evaluate the safety and effectiveness of TPE in a real-world setting in Argentina.

View Article and Find Full Text PDF

U-shaped association between post-stroke cognitive impairment and high-density lipoprotein cholesterol at the acute period of stroke.

Arch Gerontol Geriatr

August 2025

China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China. Electronic address:

Post-stroke cognitive impairment (PSCI) imposes a significant economic and social burden on patients and their families. High-density lipoprotein cholesterol (HDL-C) is reported to have protective effects on cognitive function in older adults. This study assesses the effects of HDL-C during the acute period of stroke on PSCI.

View Article and Find Full Text PDF

Background: AR1001 is a phosphodiesterase-5 inhibitor that produces improved cognitive performance and reduces amyloid-β and phosphorylated tau burdens in preclinical models of Alzheimer's disease (AD).

Objectives: To evaluate the safety and efficacy of AR1001 in participants with mild-to-moderate Alzheimer's disease (AD).

Design: Randomized, double-blind, placebo-controlled phase 2 trial conducted at 21 sites in the United States.

View Article and Find Full Text PDF